Introduction
============

Chest pain is a leading cause for physician consultation that leads to several million office and emergency department visits as well as hospital admissions yearly.[@ref1] [@ref2] Despite the use of clinical decision rules[@ref3] [@ref4] [@ref5] and the improved sensitivity of cardiac biomarkers,[@ref6] [@ref7] [@ref8] many patients who are admitted to the emergency department in order to exclude an acute coronary syndrome are ultimately found not to have a cardiac cause of their symptoms. Conversely, patients with symptoms who undergo cardiac investigations because of chest pain and are diagnosed with non-cardiac causes or in whom the cause of chest pain remains undetermined are at increased risk of subsequent cardiovascular events and death.[@ref9] [@ref10]

Guidelines published in 2012 by the American College of Cardiology Foundation/American Heart Association recommended the use of functional testing, mainly on the basis of evidence derived from studies of diagnostic accuracy (because the vast majority of diagnostic randomised trials were published after these guidelines).[@ref11] However, recent audits in large numbers of patients showed only a modest effect on subsequent diagnostic findings.[@ref12] Currently, functional and anatomical non-invasive tests are widely available and used according to locally available resources and expertise ([box](#box1){ref-type="boxed-text"}): exercise electrocardiograms, single photon emission computed tomography (CT)-myocardial perfusion imaging, stress echocardiography, real time myocardial contrast echocardiography, coronary CT angiography, and cardiovascular magnetic resonance. Among these, coronary CT angiography as the only non-invasive anatomical diagnostic modality has been suggested to overcome limitations of traditional functional testing and has undergone close scrutiny in recent years.[@ref13] [@ref14] So far, diagnostic randomised controlled trials do not provide conclusive evidence as to whether a non-invasive anatomical or functional testing strategy gives the best results for subsequent downstream testing or clinical outcomes. Therefore, we summarised the available evidence and evaluated clinical endpoints of different non-invasive diagnostic modalities in patients with symptoms suggestive of coronary artery disease through network meta-analysis.

###### Key features of widely used functional and anatomical tests for non-invasive diagnosis of coronary artery disease

Exercise electrocardiograms
---------------------------

This test aims to detect myocardial ischaemia indirectly through electrocardiographic changes during exercise and recovery, which is the physiological consequence of a mismatch between myocardial oxygen supply (coronary blood flow) and myocardial oxygen demand (myocardial work). It is a well validated tool for the assessment of functional capacity and chronotropic response to exercise.

Stress echocardiography
-----------------------

Cardiac ultrasound (echocardiography) is used to evaluate myocardial function (contractility) at rest, and during exercise or pharmacological stress. It can detect the presence and extent of coronary artery disease by provoking regional ischaemia with resulting wall motion abnormalities. Myocardial ischaemia is provoked either by exercise (treadmill or bicycle) or pharmacological agents (predominantly dobutamine).

Real time myocardial contrast echocardiography
----------------------------------------------

This test uses an intravenous echocardiographic contrast agent during stress echocardiography. While echo-contrast agents can be used to improve endocardial border definition in patients with suboptimal echocardiographic images, they also allow visualisation of myocardial tissue perfusion.

Single photon emission computed tomography-myocardial perfusion imaging
-----------------------------------------------------------------------

This technique uses intravenous administration of a radioactive myocardial perfusion tracer (radioisotope) to evaluate cardiac perfusion and function at rest and during dynamic exercise or pharmacological stress. The technique provides information on the presence or absence of myocardial ischaemia, myocardial infarction (and viability), and ventricular function.

Coronary computed tomographic angiography
-----------------------------------------

This test allows direct visualisation of the coronary artery lumen and wall using an intravenous contrast agent to produce a computed tomographic coronary angiogram. Preceding non-contrast scans can assess the presence and extent of coronary artery calcium in the vessel wall, which is a marker of extent of coronary atherosclerosis and future risk, but not necessarily related to the severity of coronary artery narrowing.

Stress cardiovascular magnetic resonance imaging
------------------------------------------------

This advanced cross sectional imaging procedure acquires two or three dimensional images of the heart. Using a contrast agent during pharmacological stress, first pass perfusion images can be used to identify areas of low myocardial blood flow (ischaemia) or stress induced regional wall motion abnormalities. During a single study, information is also provided on regional or global resting ventricular function, myocardial infarction (and viability), and proximal coronary artery anatomy.

Methods
=======

The detailed protocol that follows the template of a Cochrane review for multiple interventions is available in PROSPERO registry (CRD42016049442),[@ref15] and was prepared according to the guidelines of the Cochrane Multiple Interventions Methods Group.16

Data sources and searches
-------------------------

We performed a broad literature search in Medline, Medline in process, Embase, Cochrane Library for clinical trials, PubMed, Web of Science, SCOPUS, WHO International Clinical Trials Registry Platform, and Clinicaltrials.gov (appendix 1). A search algorithm was developed and adapted for each database, without language or sample size restrictions.

### Study selection

We included diagnostic randomised controlled trials comparing any non-invasive anatomical (evaluation of coronary anatomy) or functional (detection of myocardial ischaemia) diagnostic strategy for the detection of coronary artery disease in patients without previously known coronary artery disease but presenting with symptoms suggestive of low risk acute coronary syndrome or stable coronary artery disease. Low risk acute coronary syndrome was defined as patients typically presenting with chest pain (or anginal equivalent) for at least 5 minutes at rest within the past 24 hours, without history of known coronary artery disease, without diagnostic ischaemic changes on electrocardiogram, without haemodynamic or clinical instability, and an initial troponin level lower than the 99th percentile of the used assay. These patients typically do not need immediate assessment by invasive coronary angiography.

We also considered trials comparing any diagnostic strategy with a standard of care as defined by the authors, and trials that allowed in the same arm any diagnostic test of the same testing group (that is, functional testing). We included trials in which at least one comparative pair non-invasive diagnostic tests was available, irrespective of the number of trial arms. As a condition, we consider that within each patient group, any of the diagnostic approaches could have been applied and hence they can be considered "jointly randomiseable."[@ref17]

### Data extraction and quality assessment

Characteristics of trials, patients, and diagnostic strategies, were summarised. Details of the extracted items are available in the online protocol. Following the index diagnostic strategy, we considered as primary endpoints the subsequent referral to invasive coronary angiography and any coronary revascularisation. We considered the rate of invasive coronary angiography as an indicator of downstream testing, and the rate of revascularisation as surrogate for clinically significant coronary artery disease. Downstream testing is the need for additional diagnostic investigations that are performed (invasive or non-invasive (or both)) after the initial diagnostic test or strategy. Typically, this might occur after test failure or diagnostic uncertainty in relation to the index test result.

The outcome parameters were chosen on the basis of the hypothesis that a non-invasive, anatomically driven strategy might be more sensitive to identify non-clinically significant coronary artery disease (as suggested by previous studies), which in turn could have a prognostic effect.[@ref18] [@ref19] We also collected information on patient oriented outcomes (myocardial infarction and death), and overall downstream testing (including the number of additional diagnostic tests after the index diagnostic intervention during follow-up). In case of missing outcomes in the main and subsequent publications of the included trials, we contacted the principal investigator of each trial to provide additionally required information.

We evaluated the internal validity of the trials by using the Cochrane risk of bias tool.[@ref20] Each item was described as being at low, high, or unclear risk of bias for random sequence generation, allocation concealment, blinding (participants/personnel and outcomes), incomplete outcome data, and selective outcome reporting. We evaluated the risk of bias in each trial and pairwise comparison overall for the outcome of referral to invasive coronary angiography as low, moderate, or high risk of bias, based on our judgments for allocation concealment and blinding of outcome assessment.

Data synthesis and analysis
---------------------------

We performed the predefined analyses separately for each group of study population as defined according to clinical presentation, and for each outcome according to established meta-analytical methods.[@ref21] [@ref22] The detailed analysis plan is available in PROSPERO (CRD42016049442). Study specific odds ratios were synthesised by use of random effects pairwise and network meta-analysis.[@ref23] [@ref24] [@ref25] [@ref26] [@ref27] A treatment hierarchy was obtained according to ranking probabilities summarised with the surface under the cumulative ranking curve.[@ref28] We estimated a common heterogeneity by using restricted maximum likelihood and evaluated its magnitude by comparing the estimated variance (𝜏^2^) to its empirical distribution for pharmacological interventions and semiobjective outcomes. According to the empirical distribution, the median is 0.04 (interquartile range 0-1.58).[@ref29] Estimates around 0.04, 0.16, and 0.36 can be considered to represent a low, moderate, and high degree of heterogeneity, respectively.[@ref30] To evaluate the assumption of consistency,[@ref31] we compared the direct and indirect evidence within each loop of evidence[@ref32] and used a design by treatment test.[@ref33] In case of important heterogeneity or inconsistency, we planned to explore sources using potential effect modifiers as described in the protocol, but this was not possible owing to the low number of trials.

In primary analyses, we considered each individual diagnostic strategy separately as applied in each trial. Two trials, CRESCENT[@ref34] and PROMISE,[@ref35] randomised patients to an anatomical versus a functional diagnostic strategy using functional tests that are widely available in clinical practice (exercise electrocardiograms, stress echocardiography, and single photon emission CT-myocardial perfusion imaging). For the primary analysis, these trials were assigned as having randomised the patients to exercise electrocardiograms[@ref34] and to single photon emission CT-myocardial perfusion imaging,[@ref35] which were the most frequently used tests in each trial.

In secondary analyses, we grouped traditional functional tests in a single node and compared them with coronary CT angiography as a purely anatomical test and cardiovascular magnetic resonance as an advanced imaging modality. Cardiovascular magnetic resonance was not included in the node of functional tests because of the different nature and availability of this advance imaging modality. This merging of tests is expected to increase the power of the analysis.[@ref36] Finally, we did a sensitivity analysis by excluding the two trials[@ref34] [@ref35] that did not randomise the patients to an individual diagnostic strategy.

We calculated numbers needed to treat and numbers needed to harm for each outcome and each group of patients after grouping for functional testing as mentioned above, by applying the estimated odds ratios and confidence intervals to the odds of events estimated in patients randomly allocated to an anatomical based strategy (coronary CT angiography). For this purpose, we considered a baseline risk based on the event rates in the ACRIN-PA[@ref37] [@ref38] and PROMISE[@ref35] trials for patients presenting with low risk acute coronary syndrome and suspected of stable coronary artery disease, respectively. Both trials were the largest in each group of patients (low risk acute coronary syndrome and stable coronary artery disease) and examined the role of an anatomical testing strategy.

Analyses were performed in Stata (*network* and *network graph* packages).[@ref39] To illustrate the assessments of risk of bias for the primary outcome of referral to invasive coronary angiography, we produced a bar graph showing how much information came from high, moderate, and low risk of bias trials for each network estimate by using CINeMA (Confidence in Network Meta-Analysis) software.[@ref40] We assessed the effect of study limitations in all network meta-analysis estimates using graphs based on the contribution matrix.[@ref31]

Patient involvement
-------------------

No patients were involved in the development of the research question, development of outcome measures, design, or conduct of this study. No patients were asked to advise on interpretation or writing up of results. There are no plans to involve patients in the dissemination of the results of this study.

Results
=======

Our search yielded 19 674 citations, which were initially screened on abstract level for eligibility; 101 reports were retrieved and reviewed in full text. Finally, 30 diagnostic randomised controlled trials (34 reports) including 33 391 patients (16 083 women) and six different imaging modalities were deemed eligible ([box](#box1){ref-type="boxed-text"}, [fig 1](#f1){ref-type="fig"}, appendices 1 and 2). Appendix 3 shows the diagnostic accuracy of the evaluated imaging modalities based on previously published studies (appendix 4 lists abbreviations used). [Figure 2](#f2){ref-type="fig"} shows the diagnostic pathways chosen following the index diagnostic intervention across the trials. Descriptive details of the included trials and resulting networks are provided in [table 1](#tbl1){ref-type="table"}, [figure 1](#f1){ref-type="fig"}, and appendix 5.

![Network plots of examined diagnostic strategies across different patient groups. Network plots show comparisons across the available diagnostic strategies for each group of study populations (A and C), and consider stress echocardiography, single photon emission computed tomography-myocardial perfusion imaging, exercise electrocardiograms, or real time myocardial contrast echocardiography in the same group of diagnostic modalities of traditional functional testing (B and D). Anatomical testing pertains to coronary computed tomographic angiography. ECG=electrocardiogram; echo=echocardiography; RTMCE=real time myocardial contrast echocardiography; SPECT-MPI=single photon emission computed tomography-myocardial perfusion imaging; CCTA=coronary computed tomographic angiography; CMR=cardiovascular magnetic resonance](wins041016.f1){#f1}

![Pathways taken following the index diagnostic intervention across included diagnostic randomised controlled trials for patients with (A) low risk acute coronary syndrome and (B) suspected stable coronary artery disease. Numbers indicate total number of trials in which each index diagnostic strategy (arm of randomisation) was applied. The final list of diagnostic strategies in each graph refer to downstream tests performed after the index diagnostic strategy. \*Information on downstream testing is missing from one trial. ICA=invasive coronary angiography; ECG=electrocardiogram; echo=echocardiography; RTMCE=real time myocardial contrast echocardiography; SPECT-MPI=single photon emission computed tomography-myocardial perfusion imaging; CCTA=coronary computed tomographic angiography; CMR=cardiovascular magnetic resonance](wins041016.f2){#f2}

###### 

**Diagnostic randomised controlled trials and characteristics**

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial first author, publication year   Recruitment period             Source of funding   No of\    Comparisons                                      Sample size
                                                                                            centres                                                    
  -------------------------------------- ------------------------------ ------------------- --------- ------------------------------------------------ -------------
  Low risk acute coronary syndrome                                                                                                                     

  BEACON,[@ref41] 2016                   July 2011-January 2014         Non-industry        7         CCTA *v* standard care                           500

  Levsky et al,[@ref42] 2015             July 2008-March 2012           Non-industry        1         CCTA *v* SPECT-MPI                               400

  CT-COMPARE,[@ref43] 2014               March 2010-April 2011          Non-industry        1         CCTA *v* exercise ECG                            562

  CATCH,[@ref44] [@ref45] 2013           January 2010-January 2013      Industry related    1         CCTA *v* standard care                           600

  Lim et al,[@ref46] 2013                August 2000-May 2002           Non-industry        1         SPECT-MPI *v* standard care                      1690

  Miller et al,[@ref47] 2013             2011                           Non-industry        1         CMR *v* standard care                            105

  ROMICAT-II,[@ref48] 2012               April 2010-January 2012        Non-industry        9         CCTA *v* standard care                           1000

  ACRIN-PA,[@ref37] [@ref38] 2012        July 2009-November 2011        Non-industry        5         CCTA *v* standard care                           1392

  CT-STAT,[@ref49] 2011                  June 2007-November 2008        Industry related    16        CCTA *v* SPECT-MPI                               749

  Miller et al,[@ref50] 2011             October 2008-February 2009     Non-industry        1         CCTA *v* standard care                           60

  Miller et al,[@ref51] [@ref52] 2010    January 2008-April 2009        Non-industry        1         CMR *v* standard care                            109

  Nucifora et al,[@ref53] 2009           Not reported                   None reported       10        Stress echo *v* exercise ECG *v* standard care   290

  Chang et al,[@ref54] 2008              May 2006-February 2007         None reported       1         CCTA *v* standard care                           266

  Goldstein et al,[@ref55] 2007          March 2005-September 2005      Industry related    1         CCTA *v* standard care                           197

  Jeetley et al,[@ref56] 2007            January 2003-April 2004        Non-industry        1         Stress echo *v* exercise ECG                     433

  Nucifora et al,[@ref57] 2007           Not reported                   None reported       10        Stress echo *v* exercise ECG                     199

  Jeetley et al,[@ref58] 2006            Not reported                   None reported       1         Stress echo *v* exercise ECG                     302

  Udelson et al,[@ref59] 2002            July 1997-May 1999             None reported       7         SPECT-MPI *v* standard care                      2475

  Stable coronary artery disease                                                                                                                       

  IAEA-SPECT/CTA,[@ref60] 2016           June 2011-June 2014            Non-industry        6         CCTA *v* SPECT-MPI                               303

  CE-MARC 2,[@ref61] 2016                November 2012-March 2015       Non-industry        6         CMR *v* SPECT-MPI *v* standard care              1202

  CRESCENT,[@ref34] 2016                 April 2011-July 2013           Non-industry        4         CCTA *v* functional testing\*                    350

  Zacharias et al,[@ref62] 2016          February 2013-March 2014       None reported       1         Stress echo *v* exercise ECG                     385

  PROMISE,[@ref35] 2015                  July 2010-September 2013       Non-industry        193       CCTA *v* functional testing\*                    10 003

  SCOT-HEART,[@ref63] [@ref64] 2015      November 2010-September 2014   Non-industry        12        CCTA *v* standard care                           4146

  Laiq et al,[@ref65] 2015               October 2007-October 2011      Industry related    1         RTMCE *v* stress echo                            1649

  CAPP,[@ref66] 2015                     September 2010-November 2011   Non-industry        2         CCTA *v* exercise ECG                            500

  Porter et al,[@ref67] 2013             October 2007-December 2011     Non-industry        1         RTMCE *v* stress echo                            2063

  Min et al,[@ref68] 2012                December 2008-June 2009        Industry related    2         CCTA *v* SPECT-MPI                               180

  WOMEN,[@ref69] 2011                    Not reported                   Industry related    43        SPECT-MPI *v* exercise ECG                       824

  Sabharwal et al,[@ref70] 2007          February 2001-July 2002        Industry related    1         SPECT-MPI *v* exercise ECG                       457
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------

Trials ordered chronologically, starting from most recently published trial. ECG=electrocardiogram; echo=echocardiography; RTMCE=real time myocardial contrast echocardiography; SPECT-MPI=single photon emission computed tomography-myocardial perfusion imaging; CCTA=coronary computed tomographic angiography; CMR=cardiovascular magnetic resonance.

Functional testing includes exercise electrocardiograms, stress echocardiography, or single photon emission computed tomography-myocardial perfusion imaging, as has been defined in individual trials.

Eligible trials included patients with low risk acute coronary syndrome (18 trials, 11 329 patients)[@ref37] [@ref38] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] and suspected stable coronary artery disease (12 trials, 22 062 patients[@ref34] [@ref35] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] [@ref69] [@ref70]; [table 1](#tbl1){ref-type="table"}). The recruitment period for most of the trials was completed during the last 10 years. Seven trials reported industry related funding, 17 obtained exclusively non-industry funding, and six disclosed no funding. Fifteen trials were multicentre and two included three arm comparisons. In only three[@ref41] [@ref43] [@ref46] trials of patients with low risk acute coronary syndrome, the authors clarified the use of a high sensitive troponin assay. A diagnostic strategy based on the recommended standard of care was included in 11 trials on acute coronary syndrome and two on stable coronary artery disease. Appendix 5 provides event rates for each assessed outcome parameter. We obtained unpublished outcome data from 11 trials[@ref34] [@ref35] [@ref41] [@ref42] [@ref44] [@ref56] [@ref57] [@ref61] [@ref62] [@ref63] [@ref66] by contacting the principal investigators.

Most trials were considered to be at low risk in five of the assessed areas of potential bias, whereas no trial blinded the participants and personnel to the allocated diagnostic interventions (appendix 6). One trial[@ref43] was judged to be at high risk of bias related to random sequence generation and allocation concealment, one[@ref44] was considered high risk in relation to the blinding of outcome assessment, and one[@ref51] had possible incomplete data reporting. The risk of bias was frequently unclear, owing to limited reporting in the publications. Appendix 6 details the results of the risk of bias assessment and the contribution of comparisons with low, moderate, and high risk of bias to each network meta-analysis estimate.

Comparative efficacy of non-invasive diagnostic strategies
----------------------------------------------------------

### Patients with low risk acute coronary syndrome

Patients initially evaluated by stress echocardiography, cardiovascular magnetic resonance, or exercise electrocardiograms to exclude coronary artery disease among patients with low risk acute coronary syndrome were less likely to be referred to invasive coronary angiography compared with coronary CT angiography (odds ratio 0.28 (95% confidence 0.14 to 0.57), 0.32 (0.15 to 0.71), and 0.53 (0.28 to 1.00), respectively). However, differences were marginal for single photon emission CT-myocardial perfusion imaging (0.78 (0.58 to 1.03)) and standard of care (0.85 (0.69 to 1.05)) compared with coronary CT angiography ([fig 1A](#f1){ref-type="fig"}, [fig 3](#f3){ref-type="fig"}). Heterogeneity was low (𝜏^2^=0.023; [fig 3](#f3){ref-type="fig"}, appendix 7). Initial evaluation by coronary CT angiography yielded more frequent downstream invasive coronary angiography and ranked as the diagnostic strategy resulting in most referrals to invasive coronary angiography. There was no evidence of inconsistency (P=0.64). Most of the evidence contributing to these treatment effects was based on low to moderate risk of bias (appendix 6).

![Νetwork meta-analysis effects of examined individual diagnostic strategies versus coronary computed tomographic angiography (anatomical testing), for study group of patients with low risk acute coronary syndrome. Forest plot considers individual diagnostic strategies, as shown in [figure 1A](#f1){ref-type="fig"}. Index test indicates any diagnostic modality other than coronary computed tomographic angiography (anatomical testing). Network meta-analysis for the outcome of death was not feasible because of missing data and zero events. ECG=electrocardiogram; echo=echocardiography; SPECT-MPI=single photon emission computed tomography-myocardial perfusion imaging; CCTA=coronary computed tomographic angiography; CMR=cardiovascular magnetic resonance](wins041016.f3){#f3}

Patients evaluated by cardiovascular magnetic resonance were less likely to undergo revascularisation than those assessed by stress echocardiography (ranked as first and second diagnostic strategies, respectively). Fewer revascularisation procedures were observed among patients who were initially evaluated by cardiovascular magnetic resonance, single photon emission CT-myocardial perfusion imaging, or the standard care than by coronary CT angiography (odds ratio 0.17 (95% confidence 0.04 to 0.65), 0.57 (0.41 to 0.79), and 0.68 (0.53 to 0.88), respectively; [fig 3](#f3){ref-type="fig"}), with consistent findings between direct and indirect evidence.

Despite the differences between the diagnostic modalities in referrals for invasive coronary angiography and revascularisation, none of the strategies affected the rate of subsequent myocardial infarction, although the derived estimates were not precise. In terms of overall downstream testing, all diagnostic strategies (apart from cardiovascular magnetic resonance) were statistically significant better than a standard of care approach, which resulted in the highest rate of downstream testing (appendix 7). Significant disagreement between direct and indirect estimates was not identified, but heterogeneity was high (𝜏^2^=1.21).

After grouping of widely available functional tests (including exercise electrocardiograms, stress echocardiography, or single photon emission CT-myocardial perfusion imaging; [fig 1B](#f1){ref-type="fig"}), a functional testing strategy and cardiovascular magnetic resonance were less likely than an anatomical testing (coronary CT angiography) strategy to lead to referrals for invasive coronary angiography (odds ratio 0.71 (95% confidence interval 0.53 to 0.96) and 0.32 (0.15 to 0.72), respectively; 𝜏^2^=0.032; [fig 4](#f4){ref-type="fig"}, appendix 8). Considering overall downstream testing, a functional testing strategy was ranked first but without significant difference compared with an anatomical testing strategy. For both outcomes of downstream testing and myocardial infarction, the derived estimates were imprecise.

![Νetwork meta-analysis effects of examined grouped diagnostic strategies versus coronary computed tomographic angiography (anatomical testing), for study group of patients with low risk acute coronary syndrome. Forest plot considers grouping of functional tests, as shown in [figure 1B](#f1){ref-type="fig"}. Index test indicates any diagnostic modality other than coronary computed tomographic angiography (anatomical testing). Network meta-analysis for the outcome of death was not feasible because of missing data and zero events. CCTA=coronary computed tomographic angiography; CMR=cardiovascular magnetic resonance](wins041016.f4){#f4}

[Table 2](#tbl2){ref-type="table"} presents the estimated numbers needed to treat to prevent one event and numbers needed to harm to cause one event for different outcomes after grouping of functional diagnostic strategies. For example, in the comparison of functional testing versus anatomical testing in terms of risk of myocardial infarction, the number needed to harm was 133. The 95% confidence interval indicated that results were compatible with both a beneficial effect of a strategy based on functional versus anatomical testing, resulting in a number needed to treat to prevent one event of 194 or more. The confidence interval also indicated that results were compatible with a harmful effect of functional testing, resulting in a number needed to harm to cause one event of 25 or more.

###### 

Estimated numbers needed to treat (NNT) and numbers needed to harm (NNH) for assessed outcomes in network meta-analysis for anatomical versus functional testing. Data in brackets are 95% confidence intervals

  -------------------------------------------------------------------------------------------------------------------------------------------------------------
                                      Baseline risk†   Functional testing *v*\         Cardiovascular magnetic resonance *v*\   Standard care *v*\
                                                       anatomical testing              anatomical testing                       anatomical testing
  ----------------------------------- ---------------- ------------------------------- ---------------------------------------- -------------------------------
  Low risk acute coronary syndrome‡                                                                                             

  Invasive coronary angiography\*     7.4              NNT 49 (NNT 30 to NNT 364)      NNT 20 (NNT 16 to NNT 51)                NNT 96 (NNT 45 to NNH 210)

  Downstream testing\*                43.6             NNT 8 (NNT 3 to NNH 6)          NNH 4 (NNT 4 to NNH 2)                   NNH 3 (NNH 7 to NNH 2)

  Any revascularisation               3.0              NNT 79 (NNT 58 to NNT 155)      NNT 40 (NNT 35 to NNT 97)                NNT 106 (NNT 72 to NNT 285)

  Myocardial infarction               1.3              NNH 133 (NNT 194 to NNH 25)     NNH 52 (NNT 110 to NNH 5)                NNH 196 (NNT 432 to NNH 58)

  Stable coronary artery disease§                                                                                               

  Invasive coronary angiography\*     12.2             NNT 24 (NNT 16 to NNT 92)       NNT 20 (NNT 12 to NNH 73)                NNH 19 (NNT 92 to NNH 7)

  Downstream testing\*                21.2             NNH 35 (NNT 14 to NNH 6)        NNH 11 (NNT 8 to NNH 2)                  NNH 12 (NNT 11 to NNH 3)

  Any revascularisation               6.2              NNT 39 (NNT 28 to NNT 77)       NNT 106 (NNT 32 to NNH 40)               NNT 74 (NNT 36 to NNH 173)

  Myocardial infarction               0.6              NNH 480 (NNT 1289 to NNH 155)   NNH 102 (NNT 523 to NNH 19)              NNH 255 (NNT 16766 to NNH 95)

  Death                               1.5              NNT 6767 (NNT 250 to NNH 189)   NNH 1129 (NNT 93 to NNH 24)              NNH 252 (NNT 217 to NNH 52)
  -------------------------------------------------------------------------------------------------------------------------------------------------------------

Estimated for procedures up to three months.

Risk of events in patients receiving coronary computed tomographic angiography.

Baseline risk is based on event rates of ACRIN-PA trial.[@ref37] [@ref38]

Baseline risk is based on event rates of PROMISE trial.[@ref35]

Patients with suspected stable coronary artery disease
------------------------------------------------------

Seven individual non-invasive diagnostic strategies were examined and constitute the network of patients with symptoms assessed for suspected stable coronary artery disease ([fig 1C](#f1){ref-type="fig"}). For the outcomes of invasive coronary angiography referral and revascularisation, no individual diagnostic strategy differed from an anatomical strategy (coronary CT angiography), apart from single photon emission CT-myocardial perfusion imaging that marginally yielded less invasive coronary angiography (odds ratio 0.54 (95% confidence interval 0.30 to 0.98)) and subsequent revascularisations (0.57 (0.37 to 0.87); [fig 5](#f5){ref-type="fig"}). There was no evidence of inconsistency (P=0.62) and heterogeneity was moderate to high (𝜏^2^=0.336) for referrals to invasive coronary angiography. Overall, downstream testing favoured an initial diagnostic strategy with stress echocardiography (0.24 (0.08 to 0.74)) or single photon emission CT-myocardial perfusion imaging (0.57 (0.37 to 0.87)), but not cardiovascular magnetic resonance (0.95 (0.41 to 2.22)) compared with coronary CT angiography ([fig 5](#f5){ref-type="fig"}, appendix 9). Exercise electrocardiograms were ranked last, with the highest rate of downstream testing compared with any other diagnostic strategy. The overall heterogeneity was moderate (τ^2^=0.137).

![Νetwork meta-analysis effects of examined individual diagnostic strategies versus coronary computed tomographic angiography (anatomical testing), for study group of patients with stable coronary artery disease. Forest plot consider individual diagnostic strategies, as shown in [figure 1C](#f1){ref-type="fig"}. Index test indicates any diagnostic modality other than coronary computed tomographic angiography (anatomical testing). Real time myocardial contrast echocardiography was not included in the network meta-analysis for outcome of downstream testing because of unavailable data. ECG=electrocardiogram; echo=echocardiography; RTMCE=real time myocardial contrast echocardiography; SPECT-MPI=single photon emission computed tomography-myocardial perfusion imaging; CCTA=coronary computed tomographic angiography; CMR=cardiovascular magnetic resonance](wins041016.f5){#f5}

We detected inconsistency in the loop of coronary CT angiography, exercise electrocardiograms, and single photon emission CT-myocardial perfusion imaging, which was also verified with the sidesplit approach (P=0.48 for the inconsistency model overall). In the main analysis, we did not obtain a clear discrimination for most of the individual diagnostic strategies (imprecise estimates with broad confidence intervals and visually flat rankograms) for the clinical outcomes of myocardial infarction and death ([fig 5](#f5){ref-type="fig"}, appendix 9).

In pairwise meta-analysis, functional testing resulted in fewer referrals for invasive coronary angiography (odds ratio 0.65 (95% confidence interval 0.58 to 0.74), τ^2^\<0.001) than non-invasive anatomical testing (coronary CT angiography), with a similar estimate (0.63 (0.44 to 0.90)) from network meta-analysis after grouping of the functional tests ([fig 1D](#f1){ref-type="fig"}). Cardiovascular magnetic resonance ranked first with regards to fewer referrals for invasive coronary angiography (with an estimate of 0.37 (0.19 to 0.72)) compared with standard of care in indirect comparisons (appendix 10), although with detectable inconsistency (P\<0.05 in sidesplit approach). In the network of strategies, functional testing resulted in fewer revascularisation procedures than anatomical testing (0.57 (0.41 to 0.78); [fig 6](#f6){ref-type="fig"}), and this finding was consistent between direct and indirect evidence with low heterogeneity (τ^2^=0.029). Despite differences in referrals for invasive assessment and subsequent revascularisation, no statistical significant difference was observed for the outcome of myocardial infarction for patients who were initially evaluated with a functional or anatomical based strategy (appendix 10). However, there was a trend towards favouring an anatomical testing strategy ([fig 6](#f6){ref-type="fig"}).

![Νetwork meta-analysis effects of examined grouped diagnostic strategies versus coronary computed tomographic angiography (anatomical testing), for study group of patients with stable coronary artery disease. Forest plot considers grouping of functional tests, as shown in [figure 1D](#f1){ref-type="fig"}. Index test indicates any diagnostic modality other than coronary computed tomographic angiography (anatomical testing). CCTA=coronary computed tomographic angiography; CMR=cardiovascular magnetic resonance](wins041016.f6){#f6}

In a sensitivity analysis excluding two trials (CRESCENT[@ref34] and PROMISE[@ref35]) that randomised the patients to a non-specific functional test, the obtained estimates did not allow for any clear discrimination between the individual diagnostic strategies (appendix 11). By comparison of functional with anatomical testing in terms of risk of myocardial infarction, the number needed to harm was 480. The 95% confidence interval indicated that results were compatible with a beneficial effect of a strategy based on functional compared with anatomical testing, resulting in a number needed to treat to prevent one event of 1289 or more. The confidence interval also indicated that results were compatible with a harmful effect of functional testing, resulting in a number needed to harm to cause one event of 155 or more ([table 2](#tbl2){ref-type="table"}).

Discussion
==========

Main findings
-------------

This study assesses the available evidence derived from diagnostic randomised controlled trials of strategies to detect coronary artery disease in a systematic and comprehensive way in two different clinical settings. Firstly, among patients with low risk acute coronary syndrome not required to undergo early invasive assessment, initial functional testing in terms of stress echocardiography or cardiovascular magnetic resonance was most strongly associated with a reduction of referrals for downstream invasive coronary angiography and revascularisation procedures, compared with anatomical testing using coronary CT angiography. No diagnostic strategy had an apparent effect on the subsequent risk of myocardial infarction, although estimates were imprecise.

Secondly, among patients with symptoms suggestive of stable coronary artery disease, no clear discrimination was seen across individual diagnostic strategies for the primary outcome of invasive coronary angiography referrals, mainly because of the limited number of trials contributing to each comparison. Stress echocardiography and single photon emission CT-myocardial perfusion imaging resulted in less overall downstream testing than coronary CT angiography, whereas exercise electrocardiograms required the most further downstream testing. After grouping of widely available functional tests, a functional testing approach yielded fewer referrals for invasive coronary angiography and subsequent revascularisations than anatomical testing. Again, estimates were imprecise for the outcome of myocardial infarction, and any differences could not be ruled out.

Implications for patients with low risk acute coronary syndrome
---------------------------------------------------------------

Among patients with suspected acute coronary syndrome without relevant electrocardiographic changes and negative biomarkers, several different non-invasive modalities have been tested in trials to detect clinically relevant coronary artery disease. In this clinical setting, coronary CT angiography has shown high sensitivity and negative predictive value, although the positive predictive value using invasive coronary angiography as reference standard has been shown to be moderate.[@ref71] [@ref72]

In our meta-analysis, a diagnostic strategy based on anatomical testing with use of coronary CT angiography was associated with increased referral rates for downstream invasive coronary angiography and revascularisation, some of which could have occurred in the absence of evidence of ischaemia. High sensitivity troponin assays, which were used in a minority of the included trials in our meta-analysis, are currently available and negative test results can serve as an efficient gatekeeper of unnecessary downstream diagnostic testing in this group of patients. However, non-coronary diseases might also cause elevated levels of high sensitivity troponin and subsequently subject patients with low pretest probability for coronary artery disease to unnecessary interventions. Therefore, the selection of patients with a higher pretest probability presenting in the emergency department, the definition of higher initial cutoff values, and the focus on dynamic changes over time are key points of the appropriate diagnostic testing in this clinical setting by increasing the positive predictive value of high sensitivity cardiac troponin.[@ref73] In our analysis, the rate of clinical events was low and our estimates are therefore imprecise for risk estimates of myocardial infarction, and with wide 95% confidence intervals, cannot rule out relevant increases or reductions in the risk of myocardial infarction associated with functional testing.

Economic resources are becoming more constrained while healthcare demands are increasing in this clinical setting. Therefore, it is important to assess the comparative effectiveness of such diagnostic strategies not only in terms of safety and diagnostic accuracy, but also in terms of efficiency and cost. To this effect, we found no difference in rates of overall downstream testing between anatomical and functional based strategies, while a standard of care approach was the strategy with the highest rates of downstream testing. This result could be attributed to the fact that doctors make the final decision to refer patients for further invasive testing on the basis of factors other than initial non-invasive imaging, such as clinical presentation, persistence of symptoms, repeated clinical encounters, and patient preference.[@ref74] [@ref75] A functional testing strategy might provide important cost benefits, owing to fewer referrals for invasive coronary angiography and revascularisation and lower radiation and contrast agent exposure while resulting in similar clinical outcomes.[@ref76] Such benefits could reduce healthcare expenditure in this common clinical scenario in appropriately selected patients with low risk acute coronary syndrome. However, the availability and rapid access to functional imaging modalities (such as stress echocardiography or cardiovascular magnetic resonance) in the acute coronary syndrome setting might be limited.

Implications for patients with suspected stable coronary artery disease
-----------------------------------------------------------------------

For outpatients with suspected stable angina, our comprehensive synthesis of diagnostic randomised controlled trials indicates that an initial strategy based on functional testing might be preferable, resulting in fewer referrals for invasive coronary angiography and revascularisation. However---as was the case for the group with acute coronary syndrome---our estimates for the risk of myocardial infarction and death were imprecise, and wide 95% confidence intervals again cannot rule out relevant increases or reductions in the risk of myocardial infarction or death associated with functional testing.

Guidelines published in 2012 by the American College of Cardiology Foundation/American Heart Association recommend functional testing as the initial strategy.[@ref11] However, a concurrent use of functional and anatomical testing has been proposed on the basis of findings from two landmark trials (PROMISE[@ref35] and SCOT-HEART[@ref63] [@ref64]) that evaluated the role of coronary CT angiography in patients with suspected stable coronary artery disease.[@ref77] Our results agree with these guidelines, but contradict the recently updated guidelines from the National Institute for Health and Care Excellence (NICE). The NICE guidelines advise a non-invasive anatomical approach (coronary CT angiography) as first line diagnostic strategy with subsequent functional testing only in case of inconclusive results of the initial diagnostic test, without considering the individual pretest probability of coronary artery disease.[@ref78]

In a nationwide cohort study,[@ref79] Jorgensen and colleagues found a diagnostic approach based on non-invasive anatomical testing to be associated with modifications to cardiovascular related drug treatments, increased downstream invasive coronary testing and subsequent revascularisation, and a lower risk of myocardial infarction (hazard ratio 0.71, 95% confidence interval 0.61 to 0.82) compared with functional testing. Similarly, a conventional meta-analysis including three trials in the corresponding analysis showed a borderline significant reduction of myocardial infarction with coronary CT angiography compared with a mixture of functional testing and standard care (odds ratio 0.69 (95% confidence interval 0.49 to 0.98)).[@ref80]

In our network meta-analysis, we found a statistically non-significant signal of a similar magnitude. Results in [figure 6](#f6){ref-type="fig"} correspond to an odds ratio of myocardial infarction of 0.74 favouring coronary CT angiography over functional testing (95% confidence interval 0.48 to 1.15). However, our network meta-analysis made full use of all available evidence from 12 randomised trials comparing seven different diagnostic strategies within one analysis, appropriately quantifying the uncertainty of hard clinical outcomes associated with these strategies. Nevertheless, both the direction and magnitude of effects in our analysis are comparable with the large cohort study by Jorgensen and colleagues[@ref79] and the conventional meta-analysis.[@ref80]

A decrease in the risk of subsequent myocardial infarction related to an anatomical testing strategy is indeed possible and cannot be ruled out based on our results. However, whether intensification of medical treatment (primary or secondary prevention) or the increased rate of subsequent coronary revascularisation (or both) affect the prognosis of patients undergoing coronary CT angiography remains unknown. Finally, the baseline risk of myocardial infarction in the landmark PROMISE trial[@ref35] and the cohort study by Jorgensen and colleagues[@ref79] were low (0.6% and 0.8% for up to one month, respectively). This resulted in absolute risk differences between functional testing and coronary CT angiography of about 0.2%, with a corresponding number needed to harm around 500 for this outcome ([table 2](#tbl2){ref-type="table"}), which is arguably irrelevant to raise safety concerns.

Implications for clinicians, policymakers, and other researchers
----------------------------------------------------------------

Diagnostic tests are critical components of an effective healthcare system. Diagnostic randomised controlled trials should become the default evaluation tool for new imaging modalities and clinical outcomes.[@ref81] [@ref82] [@ref83] Our systematic evaluation show that the low event rates have resulted in sample sizes of thousands of patients in recent trials but without allowing for a clear discrimination between the individual diagnostic strategies. Along the same lines, the use of broader clinical (composite) endpoints might be clinically meaningful in future trials. More importantly, the resulting networks of trials suggest that each technological innovation became the standard for subsequent future trials (that is, coronary CT angiography), although no clear advantage in terms of clinical outcomes had been shown compared with previous diagnostic strategies. Future adequately powered clinical trials should aim to clarify the differential effects on more broadly defined clinical outcomes (which could occur during longer follow-up periods), and subsequent use of hospital resources and cost effectiveness aspects of implemented strategies, which are representative of current clinical practice.

Currently, there is a broad range of non-invasive imaging modalities to investigate patients with suspected low risk acute coronary syndrome or stable coronary artery disease, with further studies required to determine how to best integrate these tests in the patient care pathway. Several parameters such as locally available technology and expertise, patient's preferences, and relevant contraindications for each test should be taken into account when deciding on the appropriate imaging modality. Any potential benefits of the applied diagnostic test should be carefully evaluated in the context of its risks (that is, radiation exposure for coronary CT or invasive coronary angiography).

Study limitations
-----------------

This study had several limitations. Firstly, access to individual patient data that would have allowed us to identify potential differential effects in specific subgroups of patients was not available. Secondly, the low event rate of clinical outcomes (such as myocardial infarction and death) reflective of low risk populations and the sparse data for some comparisons (that is, those informed only by one trial) might have not provided enough power to clearly discriminate diagnostic strategies, especially within the stable coronary artery disease group. Thirdly, information on cost effectiveness as part of the downstream testing among the identified strategies was not given in most of the individual studies; therefore, we were not able to evaluate this aspect. Fourthly, the primary endpoints of invasive coronary angiography and revascularisation is partly attributed to physician judgment, which is not the case for the patient oriented outcomes of death and myocardial infarction. Finally, the standard of care, which was often a comparator in our study, has substantially evolved over the years. Earlier trials might not be directly relevant to present practice. However, the vast majority of the studies had been conducted in the past decade, and no differences during that period or compared with present practice are expected to have affect the results.

### What is already known on this topic

1.  Information on diagnostic accuracy is important for decisions on the usefulness of a diagnostic test, which might not translate into patient benefits

2.  Diagnostic randomised controlled trials provide the most conclusive evidence regarding patient outcomes, and represent a rigorous approach to diagnostic test evaluation

3.  Several non-invasive imaging modalities can be used to investigate patients with suspected low risk acute coronary syndromes or stable coronary artery disease, but their effect on downstream testing and clinical outcomes remains unknown and inconsistent

### What this study adds

1.  In patients with low risk acute coronary syndrome, functional testing (stress echocardiography and cardiovascular magnetic resonance) is associated with fewer referrals for downstream invasive coronary angiography than coronary computed tomographic angiography, without apparent impact on subsequent risk of myocardial infarction

2.  Among patients with suspected stable coronary artery disease, functional testing (stress echocardiography and single photon emission computed tomography-myocardial perfusion imaging) is associated with less requirement for additional diagnostic investigations (overall downstream testing) than coronary computed tomographic angiography, although the estimates cannot rule out a significant effect on the risk of myocardial infarction associated with individual tests

3.  Future adequately powered clinical trials should evaluate more broadly defined clinical outcomes, subsequent use of hospital resources, and cost effectiveness aspects of implemented strategies, which are representative of current clinical practice
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